[A21-113] Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V

Last updated 18.02.2022

Project no.:

Commission awarded on 01.09.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


Reduction of the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and

  • Established cardiovascular disease or
  • diabetes mellitus and at least one further cardiovascular risk factor
Result of dossier assessment:

Added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)
2022-02-18G-BA documents on this decision
A G-BA decision was published.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form